Understanding the biology that underlies histologically similar but molecularly distinct subgroups of cancer has proven difficult because their defining genetic alterations are often numerous, and the cellular origins of most cancers remain unknown [1] [2] [3] . We sought to decipher this heterogeneity by integrating matched genetic alterations and candidate cells of origin to generate accurate disease models. First, we identified subgroups of human ependymoma, a form of neural tumour that arises throughout the central nervous system (CNS). Subgroup-specific alterations included amplifications and homozygous deletions of genes not yet implicated in ependymoma. To select cellular compartments most likely to give rise to subgroups of ependymoma, we matched the transcriptomes of human tumours to those of mouse neural stem cells (NSCs), isolated from different regions of the CNS at different developmental stages, with an intact or deleted Ink4a/Arf locus (that encodes Cdkn2a and b). The transcriptome of human supratentorial ependymomas with amplified EPHB2 and deleted INK4A/ARF matched only that of embryonic cerebral Ink4a/Arf 2/2 NSCs. Notably, activation of Ephb2 signalling in these, but not other, NSCs generated the first mouse model of ependymoma, which is highly penetrant and accurately models the histology and transcriptome of one subgroup of human supratentorial tumour. Further, comparative analysis of matched mouse and human tumours revealed selective deregulation in the expression and copy number of genes that control synaptogenesis, pinpointing disruption of this pathway as a critical event in the production of this ependymoma subgroup. Our data demonstrate the power of cross-species genomics to meticulously match subgroup-specific driver mutations with cellular compartments to model and interrogate cancer subgroups.
Ependymomas are tumours of the brain and spinal cord 4 . Surgery and irradiation remains the mainstay of treatment of this disease because chemotherapy is ineffective in most patients. Consequently, ependymoma is incurable in up to 40% of cases 5 . Despite histologic similarities, ependymomas from different regions of the CNS show disparate prognoses, transcriptional profiles and genetic alterations 6-8 , indicating that they are different diseases and confounding efforts to study, model and treat these tumours.
To understand the biological basis of ependymoma heterogeneity, we catalogued DNA copy number alterations (CNAs) among 204 tumour samples and generated messenger (m)RNA and micro (mi)RNA expression profiles for 83 and 64 of these tumours, respectively ( Supplementary Fig. 1 , Supplementary Table 1 ). mRNA profiles segregated tumours by CNS location and unmasked previously unknown subgroups among supratentorial, posterior fossa and spinal ependymomas (subgroups A-I, Fig. 1 ). Notably, miRNAs segregated tumours by location and subgroup in a manner that matched significantly that of mRNA profiles (Rand index for mRNA subgroup match 5 0.88, P , 0.0001; Supplementary Fig. 2 ). Large chromosomal CNAs occurred most frequently in spinal tumours, enriching their mRNA expression signature for genes gained and overexpressed on chromosomes 4, 7, 9, 12, 15q and 18q and deleted and under-expressed on 22q (permutation analysis of each, P , 0.005; Supplementary Figs 3 and 4; Supplementary Table 2a ). Similarly, deletion and underexpression of chromosomes 3, 9 and 22q enriched the expression signature of subgroup C, whereas deletion and under-expression of 6q was observed in subgroup H ( Supplementary Fig. 4 ). The observation that mRNA, miRNA and CNA profiles cluster ependymomas into similar subgroups supports the notion that these subgroups are true biological entities.
In addition to large chromosomal alterations we identified 175 focal amplifications (average size 159 kilobases) and 157 focal deletions (average size 199 kb) encoding 1,236 and 1,209 transcripts, respectively (see Supplementary Methods, Supplementary Table 3 and Supplementary Gene Cards). In contrast to large alterations, focal CNAs occurred most frequently in supratentorial ependymomas ( Supplementary Table 2b ). Alignment of each focal CNA against the database of copy number variants (CNVs) revealed which overlapped with known CNVs (http://projects.tcag.ca/variation/), but these were not excluded from further analysis because recent data indicate that CNVs might contribute to disease states, including cancer 9 . Fifty-one of 57 selected CNAs that were likely to encode oncogenes or tumour suppressor genes (TSGs) were validated by real-time PCR and/or fluorescence in situ hybridization (FISH) ( Fig. 1 ; Supplementary Table 4 ; Supplementary Gene Cards; see Supplementary Methods for selection criteria). This extensive analysis confirmed and refined previously reported CNAs (for example, deletion of CDKN2A 7 , amplification of NOTCH1, ref. 8, and three discrete focal 22q deletions), and identified 28 and 23 novel recurrent focal amplifications and deletions, respectively.
To prioritize for further study genes within focal CNAs that may have driven clonal selection, we correlated DNA copy number with the level of transcripts encoded by each affected locus (Supplementary Gene Cards). Seventeen percent (n 5 107/632) of genes located within 28 validated focal amplicons showed evidence of copy-number-driven expression, highlighting them as potential ependymoma oncogenes ( Supplementary Table 5a ). Notably, these included several regulators of stem cell proliferation, pluripotency and neural differentiation for example, THAP11 (ref. 10 8 . Eighteen-percent (n 5 130/728) of genes located within 23 validated focal deletions showed copy-number-driven decreased expression compatible with these being TSGs ( Supplementary  Table 5b and Supplementary Gene Cards). These included established TSGs implicated previously in ependymoma 7 (for example PTEN, INK4A/ARF), as well as genes with no previously known role in cancer (for example STAG1 [3q22.3] and TNRC6B [22q13.1]). Because the few known candidate ependymoma oncogenes and TSGs were identified by our comprehensive bioinformatics, we suggest that the other genes identified here are highly enriched for those involved in ependymoma tumorigenesis.
Recently, we showed that intracranial and spinal ependymomas are propagated by radial glia-like cancer stem cells 7 . Radial glia function as NSCs in the embryo and give rise to adult NSCs 19, 20 . Throughout development NSCs located in the different regions of the CNS show intrinsic biological differences that include the expression of variable transcription factor profiles and the production of different kinds of neurons 19, 21 . Therefore, we reasoned that individual subgroups of ependymoma might arise from regionally and developmentally distinct NSCs that are susceptible to transformation by different gene mutations. To test this hypothesis, we first established a robust source of radial glia (hereafter called embryonic NSCs) and adult NSCs. Enhanced green fluorescent protein (eGFP) 1 cells were isolated from the cerebrum, hindbrain and spine of embryonic day (E) 14.5 and adult Blbp-eGFP (Blbp is also known as Fabp7) transgenic mice that express eGFP within the embryonic NSC-astroglial-adult NSC lineage [22] [23] [24] (Fig. 2) . eGFP 1 cells were isolated from both Ink4a/Arf 1/1 and Ink4a/Arf 2/2 mice because this locus is frequently deleted from human supratentorial ependymomas ( Fig. 1; Supplementary Gene Cards) . When cultured under conditions that promote stem cell growth, all 12 distinct eGFP 1 cell isolates were demonstrated to be NSCs that had a Nestin 1 /Prom1 1 /Gfap 1 / Rc2 1 /Blbp 1 immunophenotype 19 (Nestin also known as Nes) and self-renewed as clonal multipotent neurospheres ( Fig. 2a, b ; Supplementary Fig. 5 ). mRNA expression profiles of 177 separate NSC cultures segregated these cells according to location (intracranial versus spine) and developmental stage (embryonic versus adult), and further segregated adult intracranial NSCs by brain region (cerebral versus hindbrain) and Ink4a/Arf status (Fig. 2b) . Notably, cerebral and hindbrain NSCs isolated from Ink4a/Arf 2/2 adult mice showed an increased self-renewal capacity (Fig. 2b) . Together, these data confirm functional differences between regionally, developmentally and genetically defined NSC isolates and validate reports that increasing Cdkn2a expression negatively regulates self-renewal in ageing cerebral NSCs 25 .
To pinpoint which NSCs might give rise to ependymoma subgroups, we developed a novel algorithm that we termed agreement of differential expression (AGDEX) that detects transcriptomic similarities between tissues from different species by comparing the expression of shared orthologues (see Supplementary Methods) . The transcriptome of supratentorial ependymomas significantly matched only that of embryonic cerebral Ink4a/Arf 2/2 NSCs (n 5 14,261 orthologues, permuted P , 0.05). Conversely, spinal ependymomas were most similar to adult spinal NSCs (permuted P , 0.005). Interestingly, these development-dependent correlations reflect the epidemiology of the disease: supratentorial ependymomas affect three times more paediatric than adult patients, whereas spinal ependymomas are five times more common in adults 26 . These data pinpoint embryonic cerebral NSCs and adult spinal NSCs as putative cells of origin of supratentorial and spinal ependymoma, respectively, and support genetic evidence that deletion of the INK4A/ARF locus is important in the development of supratentorial ependymoma.
To test directly if embryonic cerebral Ink4a/Arf 2/2 NSCs represent a specific source of supratentorial ependymomas, we challenged these cells with Ephb2 that we identified to be selectively amplified and/or overexpressed in these tumours (Fig. 3a, b ) and that was shown recently to regulate stem cell proliferation and tumorigenesis in the intestine 27 . For comparative purposes, we also challenged a panel of four other NSC isolates ( Fig. 3c, d ). Freshly isolated eGFP 1 NSCs were transduced at second neurosphere passage with Ephb2-red fluorescence protein (EphB2 RFP ) or control (cRFP) viruses ( Fig. 3c ). eGFP 1 /RFP 1 NSCs (1 3 10 6 ) were then implanted in the cerebrum of immunocompromised mice that were observed for signs of tumour development. None of 120 mice implanted with controltransduced NSCs developed tumours (median follow up 227 days, Fig. 3d ). Mice implanted with Ephb2 RFP -transduced embryonic cerebral Ink4a/Arf 1/1 , adult cerebral Ink4a/Arf 2/2 , embryonic hindbrain Ink4a/Arf 2/2 or adult spinal Ink4a/Arf 2/2 NSCs developed tumours with non-ependymal histologies at very low rates (9.6%, n 5 9/94 median follow up 241 days; Fig. 3d ; Supplementary Fig.  6 ). In contrast, 50% of mice implanted with Ephb2 RFP -transduced embryonic cerebral Ink4a/Arf 2/2 NSCs developed EphB2 1 /eGFP 1 / RFP 1 brain tumours within 200 days of implantation, and less than 30% were tumour-free by 300 days (log-rank P , 0.0005, median follow up 230 days, Fig. 3d ). Notably, these mouse tumours were histologically indistinguishable from human ependymomas, displaying characteristic pseudo-rosettes, a uniform (non-nodular) distribution of cells and clear cell phenotype-all hallmarks of certain supratentorial ependymomas (Fig. 4a) 28 . Furthermore, electron microscopy identified microvilli, cilia and tight junctions in these mouse tumours that are classic ultrastructural features of human ependymoma (Fig. 4b) . Thus, the specific combination of embryonic cerebral NSCs, deletion of Ink4a/Arf and amplification of EphB2 generates supratentorial ependymoma, supporting strongly the hypothesis that ependymoma variants arise from specific combinations of susceptible NSCs and matched mutations. To test further the fidelity of this new mouse model of supratentorial ependymoma, we used the AGDEX algorithm to correlate the orthologue expression profiles of 12 Ephb2-driven mouse ependymomas with those of human ependymoma subgroups (A-I) as well as previously described molecular subgroups of human glioblastoma 29 and medulloblastoma 30 . This analysis confirmed a highly significant and selective match between mouse and human supratentorial ependymoma, but no other tested human brain tumour (permuted P , 0.0001, Fig. 4c ). Notably, the transcriptome of our mouse model matched a single human supratentorial ependymoma subgroup (D), validating subgroup D as a true disease entity. Review of the orthologues that were most significantly and differentially expressed in both Ephb2-driven mouse ependymomas (relative to embryonic cerebral Ink4a/Arf 2/2 NSCs) and human subgroup D tumours (relative to other human tumours) showed these to be highly enriched for regulators of neural differentiation and maintenance, particularly ion transport and synaptogenesis (n 5 70/160, Fisher's exact test, Q , 0.0001, Supplementary Table 6 ). Eleven of these common signature orthologues were also targeted by CNAs in subgroup D tumours, of which six directly regulate neurogenesis and maintenance ( Supplementary Table 6 ). Thus, we predict that aberrant EPHB2 signalling and deletion of Ink4a/Arf disrupt key neural differentiation pathways in embryonic cerebral NSCs during the formation of subgroup D ependymoma. We describe a novel cross-species genomic approach that meticulously matches subgroup-specific driver mutations and appropriate cellular compartments to model human cancer subgroups. Similar efforts are underway to model and validate the remaining human ependymoma subgroups. The approach described here could be applied to other cancers, enabling the identification and matching of candidate cells of origin with appropriate mutations to decipher molecular subgroups.
METHODS SUMMARY
Tissue samples and genomics. Human ependymoma samples were obtained from tumour banks with Institutional Review Board approval. Human and mouse tumours comprised a minimum of 85% tumour cells. Expression profiles were generated using Affymetrix U133 Plusv2 (mRNA human) and 430v2 (mRNA mouse) arrays and Agilent miRNA arrays (human). Expression profiles of 53 human medulloblastomas and 76 glioblastomas were obtained from studies published previously 29, 30 . DNA copy number analyses were performed using the Affymetrix 500K SNP mapping arrays. CNAs were validated by real-time PCR (see Supplementary Table 4 ) and/or FISH as appropriate 7 . mRNA and miRNA expression profiles and DNA CNAs were analysed, validated and integrated using established and novel bioinformatic and statistical approaches (see Supplementary Methods) . Common orthologues were filtered from human mouse mRNA expression arrays using sequence mapping. NSC cultures and implants. Blbp-eGFP transgenic mice were the generous gift of N. Heintz, FVB.129-Cdkn2a tm1Rdp mice were from the MMHCC repository. eGFP 1 cells were isolated from Blbp-eGFP mouse brains and spines and cultured in neural stem cell medium as described 7 . NSCs were transduced with RFPretroviruses and eGFP 1 /RFP 1 cells sorted using a Becton Dickinson Aria II Cell Sorter. Clonal neurosphere formation and differentiation capacities were assessed in serial dilutions of single-cell suspensions 7 . NSCs were implanted under stereotactic control into the forebrain of immunocompromised mice and animals were observed daily for signs of tumour development 7 . All mouse brains were inspected by macroscopic dissection post-mortem. Fresh tumour cells were recovered from mouse brains as described 7 . Histology. Sections of human and mouse ependymomas were prepared from formalin-paraffin-embedded tissues. Protein expression was detected in formalin fixed tissue sections and differentiated NSCs using standard immunohistochemical and immunofluorescence techniques. Electron microscopy was performed using standard tissue preparations and a FEI Tecnai 20 200KV FEG Electron Microscope. Western blot analysis was used to detect protein expression in fresh tissue and cells (for antibodies see Supplementary Methods ).
